Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 2/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.55 |
| ▸ | BRAF | P15056 | 10/20 | 0.55 |
| ▸ | RAF1 | P04049 | 9/20 | 0.55 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7692421 | 0.88 | MAPK13 (0.60) | MAPK13PIK3CAAURKARPS6KB1MAPK14 | |
| SCHEMBL12763857 | 0.87 | MAPK13 (0.61) | MAPK13PIK3CAMAPK14BRAFRAF1 | |
| SCHEMBL4833935 | 0.83 | NPC1 (0.61) | MAPK13PIK3CAMAPK14BRAFRAF1 | |
| SCHEMBL5897176 | 0.83 | MAPK13 (0.62) | MAPK13PIK3CAMAPK14BRAFRAF1 | |
| SCHEMBL4827539 | 0.83 | MAPK14 (0.66) | MAPK13MAPK14BRAFRAF1HSPB1 | |
| SCHEMBL31524076 | 0.83 | MAPK14 (0.66) | MAPK13MAPK14BRAFRAF1HSPB1 | |
| SCHEMBL4831994 | 0.81 | MAPK14 (0.57) | MAPK13AURKARPS6KB1MAPK14BRAF | |
| SCHEMBL27461654 | 0.81 | MAPK13 (0.60) | MAPK13PIK3CAAURKARPS6KB1MAPK14 | |
| SCHEMBL12764085 | 0.81 | MAPK14 (0.69) | MAPK13MAPK14BRAFRAF1HSPB1 | |
| SCHEMBL1517272 | 0.81 | RAF1 (0.57) | MAPK13PIK3CABRAFRAF1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | disclosed |
| CN-1158266-C | Chemical compounds | — | 2004-07-21 | — | — | CN | disclosed |
| US-6716847-B2 | ANTIALLERGENS, ANTIINFLAMMATORY | ASTRAZENECA AB (SE) | 2004-04-06 | — | — | US | disclosed |
| US-20030216417-A1 | Substituted anilino-quinoline compounds and use thereof | ASTRAZENECA AB | 2003-11-20 | — | — | US | disclosed |
| US-6593333-B1 | Processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines. Tumour Necrosis Factor (hereinafter TNF), for example TNF alpha , and various | ASTRAZENECA AB (SE) | 2003-07-15 | — | — | US | disclosed |
| EP-1117653-B1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-02-05 | — | — | EP | disclosed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| CN-1321151-A | Chemical compounds | ASTRAZENECA AB (SE) | 2001-11-07 | — | — | CN | disclosed |
| EP-1117653-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
| WO-2000020402-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | MAPK13 3593/4885PIK3CA 4493/4885AURKA 3640/4885 |
| US-20060281734-A1 | Amide derivatives | IL6, IL6ST, IL1B | MAPK13 3593/4885PIK3CA 4493/4885AURKA 3640/4885 |
| US-20030216417-A1 | Substituted anilino-quinoline compounds and use thereof | IL6, IL6ST, IL1A | MAPK13 3212/4885PIK3CA 2330/4885AURKA 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.